findings

Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial

Company Announces Approximately $30 Million in Cash and Short-Term Investments Following Its October 27th Registered Direct Offering November 24, 2025…

3 hours ago

IBM Study: Chief Data Officers Redefine Strategies as AI Ambitions Outpace Readiness

81% of Chief Data Officers surveyed prioritize investments that accelerate AI capabilities and initiatives. 78% of surveyed leaders cite leveraging…

2 weeks ago

Zscaler ThreatLabz Reveals 67% Jump in Android Malware and 40% of IoT Attacks Target Critical Industries and Hybrid Work

Key Findings: Critical infrastructure in the energy sector experienced a 387% increase in attacks compared to the previous yearIndia continues…

3 weeks ago

Baylor Genetics to Highlight Genetic Testing Use Cases and Advancements in Rare Disease at The National Society of Genetic Counselors 44th Annual Conference

HOUSTON, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, will…

3 weeks ago

Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025

Expanded cohort reiterates strong adherence rate of over 90% for Shield blood-based colorectal cancer screening test Survey findings show eligible…

4 weeks ago

ACM Biolabs Reports Favorable Safety Signals and Early Pharmacodynamics from Intramuscular Administration of ACM-CpG in Patients with Advanced Solid Tumors

SINGAPORE, Oct. 22, 2025 /PRNewswire/ -- ACM Biolabs, a clinical-stage biotechnology company developing next-generation nanoparticle-based immunotherapies, today announced encouraging early clinical findings…

1 month ago

World’s Leading Nutrition Researchers Discuss Future Lines of Research on Nuts and Dried Fruit at NUTS 2025

REUS, Spain, Oct. 22, 2025 /PRNewswire/ -- Leading health researchers from around the world have identified new priorities and directions…

1 month ago

Subcutaneous RYBREVANT(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer

Responses were rapid and durable, and tumour shrinkage was observed in 82 percent of patients1 New findings from this investigational…

1 month ago

HKUST Scientists Reveal Critical Impacts of a Chinese Genetic Risk Factor in Alzheimer’s Disease

HONG KONG, Oct. 2, 2025 /PRNewswire/ -- A landmark study conducted by The Hong Kong University of Science and Technology…

2 months ago

CeraVe and L’Oral Groupe Win Prestigious IFSCC Applied Research Award for Breakthrough Dandruff Study

New findings reveal critical microbial drivers, ethnic variations, and new pathways for personalized scalp care NEW YORK, Sept. 29, 2025…

2 months ago